

AUTHOR INDEX FOR VOLUME 35

A

- Abe, A., *see* Yasumori, T., 443
 Abu-Zeid, M., *see* Yamazoe, Y., 707
 Albuquerque, E. X., *see* Swanson, K. L., 223
 Alho, H., *see* Szekely, A. M., 401
 Ambler, S. K., and Taylor, P. Release of nonmitochondrial sequestered Ca^{2+} from permeabilized muscle cells in culture, 369
 Amiche, M., Sagan, S., Mor, A., Delfour, A., and Nicolas, P. Dermen-kephalin (Tyr-D-Met-Phe-His-Leu-Met-Asp-NH₂): A potent and fully specific agonist for the δ opioid receptor, 774
 Anderson, D., *see* McKinney, M., 39
 Aracava, Y., *see* Swanson, K. L., 223
 Arcamone, F., *see* Gresh, N., 251
 Aronstam, R. S., *see* Swanson, K. L., 223
 Asai, D. J., *see* O'Brien, E. T., 635
 Astroff, B., *see* Harris, M., 729

B

- Baba, M., *see* Balzarini, J., 571
 Balfour, C., *see* Halpert, J., 148
 Balzarini, J., *see* Ono, K., 578
 Balzarini, J., Van Aerschot, A., Pauwels, R., Baba, M., Schols, D., Herdewijn, P., and De Clercq, E. 5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): Potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine, 571
 Barbaccia, M. L., *see* Szekely, A. M., 401
 Barhanin, J., *see* Schmid, A., 766
 Barrett, R. W., Steffey, M. E., and Wolfram, C. A. W. Type-A cholecystokinin receptors in CHP212 neuroblastoma cells: Evidence for association with G protein and activation of phosphoinositide hydrolysis, 394
 Baur, R., *see* Yao, Y., 319
 Beck, S. G., *see* Zgombick, J. M., 484
 Beckmann, R. P. and Beerman, T. A. Use of an inducible hybrid viral gene as a model for evaluating drug effects of gene expression, 433
 Beer, B., *see* Hirsch, J. D., 157
 Beerman, T. A., *see* Beckmann, R. P., 433
 Beerman, T. A., *see* Woynarowski, J. M., 177
 Behrendt, J., *see* Michel, M. C., 324
 Beitner, D. B., Duman, R. S., and Nestler, E. J. A novel action of morphine in the rat locus coeruleus: Persistent decrease in adenylyl cyclase, 559
 Belinsky, S. A., Kauffman, F. C., and Thurman, R. G. Interactions between glycolysis and mixed function oxidation: Studies with 7-ethoxycoumarin in perfused livers from β -naphthoflavone-treated rats, 512
 Berger, S. H., *see* Davis, S. T., 422
 Berrie, C. P., Hawkins, P. T., Stephens, L. R., Harden, T. K., and Downes, C. P. Phosphatidylinositol 4,5-bisphosphate hydrolysis in turkey erythrocytes is regulated by P₂ purinoceptors, 526
 Beveridge, A. J., *see* McKenna, R., 720
 Beyer, C. F., *see* Hirsch, J. D., 157, 164
 Billedeau, R. J., *see* Killackey, J. J. F., 701
 Birdsall, N. J. M., *see* Eveleigh, P., 477
 Blair, T. A., Parenti, M., and Murray, T. F. Development of pharmacological sensitivity to adenosine analogs in embryonic chick heart: role of A₁ adenosine receptors and adenylyl cyclase inhibition, 661

- Bloom, S. E., *see* Lorr, N. A., 610
 Blume, A. J., *see* Hirsch, J. D., 157, 164
 Bock, M. G., *see* Chang, R. S. L., 803
 Boelsterli, J. J., *see* Seiler, M. P., 643
 Bonaventura, B. J., *see* Killackey, J. J. F., 701
 Bonner, F. W., *see* Gartland, K. P. R., 242
 Bonner, T. I., *see* Buckley, N. J., 469
 Boulay, G., *see* Guillemette, G., 339
 Brann, M. R., *see* Buckley, N. J., 469
 Bristow, M. R., Hershberger, R. E., Port, J. D., Minobe, W., and Rasmussen, R. β_1 - and β_2 -Adrenergic receptor-mediated adenylyl cyclase stimulation in nonfailing and failing human ventricular myocardium, 295
 Brodde, O.-H., *see* Michel, M. C., 324
 Buckley, C. M., *see* Buckley, N. J., 469
 Buckley, N. J., Bonner, T. I., Buckley, C. M., and Brann, M. R. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells, 469
 Burstein, S. H., Hull, K., Hunter, S. A., and Shilstone, J. Immunization against prostaglandins reduces Δ^1 -tetrahydrocannabinol-induced catalepsy in mice, 6
 Busche, R., Tümmeler, B., Riordan, J. R., and Cano-Gauci, D. F. Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance, 414
 Bushfield, M., *see* Johnson, R. A., 681

C

- Canela, E. I., *see* Orozco, M., 257
 Cano-Gauci, D., *see* Busche, R., 414
 Castelhamo, A. L., *see* Killackey, J. J. F., 701
 Chang, R. S. L., Chen, T. B., Bock, M. G., Freidinger, R. M., Chen, R., Rosegay, A., and Lotti, V. J. Characterization of the binding of [³H]L-365,260: A new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand, 803
 Chen, R., *see* Chang, R. S. L., 803
 Chen, S., *see* Liu, X.-F., 818
 Chen, T. B., *see* Chang, R. S. L., 803
 Cheung, A. H., Sigal, I. S., Dixon, R. A. F., and Strader, C. D. Agonist-promoted sequestration of the β_2 -adrenergic receptor requires regions involved in functional coupling with G_s, 132
 Chijiwa T., *see* Ishikawa, T., 760
 Ciriolo, M. R., *see* Magliozzo, R. S., 428
 Cook, J. C. and Greenlee, W. F. Characterization of a specific binding protein for 2,3,7,8-tetrachlorodibenzo-*p*-dioxin in human thymic epithelial cells, 713
 Correia, M. A., *see* Lunetta, J. M., 10
 Costa, E., *see* Szekely, A. M., 401
 Cox, R. F., and Waszczak, B. L. Differences in dopamine receptor reserve for *N*-*n*-propylmorphine enantiomers: Single unit studies after partial inactivation of receptors by *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, 125
 Craddock-Royal, B., *see* Zgombick, J. M., 484
 Criscione, K. R., *see* Grunewald, G. L., 93
 Czajkowski, C., and Farb, D. H. Identification of an intracellular pool of γ -aminobutyric acid_A-benzodiazepine receptors en route to the cell surface of brain neurons in culture, 183
 Czajkowski, C., Gibbs, T. T., and Farb, D. H. Transmembrane topology of the γ -aminobutyric acid_A-benzodiazepine receptor: Subcellular distribution and allosteric coupling determined *in situ*, 75

D

- Davis, S. T. and Berger, S. H. Modulation of 5-fluoro-2'-deoxyuridine response by folinic acid in human colonic tumor cell lines. The role of thymidylate synthase, 422
- Dawson, G., *see* Francel, P. C., 34
- De Clercq, E., *see* Balzarini, J., 571
- De Clercq, E., *see* Ono, K., 578
- de Costa, B. R., *see* Lewin, A. H., 189
- De Lean, A., *see* F  thi  re, J., 584
- Delfour, A., *see* Amiche M., 774
- De Matteis, F., Trenti, T., Gibbs, A. H., and Greig, J. B. Inducible bilirubin-degrading system in the microsomal fraction of rat liver, 831
- Denny, W. A., *see* McKenna, R., 720
- Deyoung, L., *see* Killackey, J. J. F., 701
- Dhar, A., *see* Shukla, S. D., 409
- Dingledine, R., *see* Verdoorn, T. A., 360
- Dixon, R. A. F., *see* Cheung, A. H., 132
- Domask, L. M., *see* Fisher, S. K., 195
- Downes, C. P., *see* Berrie, C. P., 526
- Duman, R. S., *see* Beitner, D. B., 559

E

- Eens, A., *see* Leysen, J. E., 375
- Ellis, J., and Seidenberg, M. Gallamine exerts biphasic allosteric effects at muscarinic receptors, 173
- Eveleigh, P., Hulme, E. C., Schudt, C., and Birdsall, N. J. M. The existence of stable enantiomers of telenezepine and their stereoselective interaction with muscarinic receptor subtypes, 477
- Evoniuk, G., Moody, E. J., and Skolnick, P. Ultraviolet irradiation selectively disrupts the γ -aminobutyric acid/benzodiazepine receptor-linked chloride ionophore, 695

F

- Farb, D. H., *see* Czajkowski, C., 75, 183
- Farmer, W., *see* Killackey, J. J. F., 701
- Feldman, R. D. β -adrenergic desensitization reduces the sensitivity of adenylate cyclase for magnesium in permeabilized lymphocytes, 304
- Ferrendelli, C. A., *see* Potter, L. T., 652
- F  thi  re, J., Meloche, S., Nguyen, T. T., Ong, H., and De Lean, A. Distinct properties of atrial natriuretic factor receptor subpopulations in epithelial and fibroblast cell lines, 584
- Fine, J. S., Gasiewicz, T. A., and Silverstone, A. E. Lymphocyte stem cell alterations following perinatal exposure to 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 18
- Fischer, P. H., *see* Vazquez-Padua, M. A., 98
- Fisher, S. K., Domask, L. M., and Roland, R. M. Muscarinic receptor regulation of cytoplasmic Ca^{2+} concentrations in human SK-N-SH neuroblastoma cells: Ca^{2+} requirements for phospholipase C activation, 195
- Ford, J. M., Prozialeck, W. C., and Hait, W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance, 105
- Francel, P. C., Keefer, J. F., and Dawson, G. Bradykinin analogs antagonize bradykinin-induced second messenger production in a sensory neuron cell line, 34
- Franco, R., *see* Orozco, M., 257
- Freidinger, R. M. *see* Chang, R. S. L., 803
- Friedman, F. K., *see* Lorr, N. A., 610
- Fukasawa, T., *see* Yasumori, T., 443

G

- Gago, F., Reynolds, C. A., and Richards, W. G. The binding of nonintercalative drugs to alternating DNA sequences, 232
- Galitzky, J., *see* Paris, H., 345
- Gannon, M. N., Hough, L. B., and Weinstein, H. A metactoid sensi-

- zation model to describe multiple receptors linked to a common response: Application to histamine receptors coupled to [^3H]cyclic AMP accumulation in guinea pig cortex, 205
- Gartland, K. P. R., Bonner, F. W., and Nicholson, J. K. Investigations into the biochemical effects of region-specific nephrotoxins, 242
- Gasiewicz, T. A., *see* Fine, J. S., 18
- Gasser, R. and Philpot, R. M. Primary structures of cytochrome P-450 isozyme 5 from rabbit and rat and regulation of species-dependent expression and induction in lung and liver: Identification of cytochrome P-450 gene subfamily IVB, 617
- Gelboin, H. V., *see* Lorr, N. A., 610
- Gelboin, H. V., *see* Riddick, D. S., 626
- Gibbs, A. H., *see* De Matteis, F., 831
- Gibbs, T. T., *see* Czajkowski, C., 75
- Girard, P. R., *see* Parente, J. E., 26
- Gistrak, M. A., *see* Price, M., 67
- Gnegy, M. E., *see* Roseboom, P. H., 139
- Gong, D., *see* Yamazoe, Y., 707
- Gonzalez, R. A., and Moerschbaecher, J. M. A phencyclidine recognition site is associated with *N*-methyl-D-aspartate inhibition of carbachol-stimulated phosphoinositide hydrolysis in rat cortical slices, 787
- Greenlee, W. F., *see* Cook, J. C., 713
- Greig, J. B., *see* De Matteis, F., 831
- Gresh, N., Pullman, B., Arcamone, F., Menozzi, M., and Tonani, R. Joint experimental and theoretical investigation of the comparative DNA binding affinities of intercalating anthracycline derivatives, 251
- Grunewald, G. L., Ye, Q., Sall, D. J., Criscione, K. R., and Wise, B. Conformational and steric aspects of phenylethanolamine and phenylethylamine analogues as substrates or inhibitors of phenylethanolamine *N*-methyltransferase, 93
- Guillemette, G., Lamontagne, S., Boulay, G., and Mouillac, B. Differential effects of heparin on inositol 1,4,5-trisphosphate binding, metabolism, and calcium release activity in the bovine adrenal cortex, 339
- Guzelian, P. S., *see* Hostetler, K. A., 279

H

- Haga, K., Uchiyama, H., Haga, T., Ichiyama, A., Kangawa, K., and Matsuo, H. Cerebral muscarinic acetylcholine receptors interact with three kinds of GTP-binding proteins in a reconstitution system of purified components, 286
- Haga, T. *see* Haga, K., 286
- Hagiwara, M., *see* Ishikawa, T., 760
- Hahn, E. F., *see* Price, M., 67
- Hait, W. N., *see* Ford, J. M., 105
- Halm, E., *see* Nestler, E. J., 265
- Halpert, J., Jaw, J.-Y., and Balfour, C. Specific inactivation by 17 β -substituted steroids of rabbit and rat liver cytochromes P-450 responsible for progesterone 21-hydroxylation, 148
- Hanchett, H. E., *see* Potter, L. T., 652
- Haniu, M., *see* Liu, X.-F., 818
- Harden, T. K., *see* Berrie, C. P., 526
- Harper, P. A., *see* Okey, A. B., 823
- Harris, M., Zacharewski, T., Astroff, B., and Safe, S. Partial antagonism of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-mediated induction of aryl hydrocarbon hydroxylase by 6-methyl-1,3,8-trichlorodibenzo-furan: Mechanistic studies, 729
- Hawkins, P. T., *see* Berrie, C. P., 526
- Hawrot, E., *see* McLaughlin, J. T., 593
- Heasley, L. E., and Johnson, G. L. Detection of nerve growth factor and epidermal growth factor-regulated protein kinases in PC12 cells with synthetic peptide substrates, 331
- Herdewijn, P., *see* Balzarini, J., 571
- Herdewijn, P., *see* Ono, K., 578
- Hershberger, R. E., *see* Bristow, M. R., 295

- Hidaka, H., *see* Ishikawa, T., 760
Hinkle, P. M., *see* Phillips, W. J., 533
Hirsch, J. D., Beyer, C. F., Malkowitz, L., Beer, B., and Blume, A. J. Mitochondrial benzodiazepine receptors mediate inhibition of mitochondrial respiratory control, 157
Hirsch, J. D., Beyer, C. F., Malkowitz, L., Loullis, C. C., and Blume, A. J. Characterization of ligand binding to mitochondrial benzodiazepine receptors, 164
Hoffman, B. B., *see* Thomas, J. M., 116
Hollifield, M. A., *see* Potter, L. T., 652
Hollingsworth, E. B. Gastrin-releasing peptide receptor in rat brain membranes: Specific binding and stimulation of phosphoinositide breakdown, 689
Hosey, M. M., *see* Kwatra, M. M., 553
Hostetler, K. A., Wrighton, S. A., Molowa, D. T., Thomas, P. E., Levin, W., and Guzelian, P. S. Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents, 279
Hough, L. B., *see* Gannon, M. N., 205
Hsu, A. H.-M., *see* Hwang, S.-B., 48
Hull, K., *see* Burstein, S. H., 6
Hulme, E. C., *see* Eveleigh, P., 477
Hunter, S. A., *see* Burstein, S. H., 6
Hwang, S.-B., Lam, M.-H., and Hsu, A. H.-M. Characterization of platelet-activating factor (PAF) receptor by specific binding of [³H]L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: Possible multiple conformational states of a single type of PAF receptors, 48
- I**
- Ichiyama, A., *see* Haga, K., 286
Insel, P. A., *see* Michel, M. C., 324
Ishikawa, T., Chijiwa, T., Hagiwara, M., Mamiya, S., and Hidaka, H. Thyroid hormones directly interact with vascular smooth muscle strips, 760
Itzhak, Y., *see* Price, M., 67
Iyanagi, T., *see* Liu, X.-F., 818
- J**
- Jacobs, R. S., *see* O'Brien, E. T., 635
Jahr, C. E., *see* Lester, R. A. J., 565
Janssen, P. A. J., *see* Leysen, J. E., 375
Javitt, D. C. and Zukin, S. R. Biexponential kinetics of [³H]MK-801 binding: Evidence for access to closed and open *N*-methyl-D-aspartate receptor channels, 387
Jaw, J.-Y., *see* Halpert, J., 148
Jenkins, T. C., *see* McKenna, R., 720
Johlin, F. C., Swain, E., Smith, C., and Tephly T. R. Studies on the mechanism of methanol poisoning: Purification and comparison of rat and human liver 10-formyltetrahydrofolate dehydrogenase, 745
Johnson, G. L., *see* Heasley, L. E., 331
Johnson, R. A., Yeung, S.-M. H., Stübner, D., Bushfield, M., and Shoshani, I. Cation and structural requirements for P site-mediated inhibition of adenylate cyclase, 681
Joseph, S. K. and Rice, H. L. The relationship between inositol triphosphate receptor density and calcium release in brain microsomes, 355
- K**
- Kangawa, K., *see* Haga, K., 286
Karlsson, M. O., and Neil, A. Estimation of ligand binding parameters by simultaneous fitting of association and dissociation data: A Monte Carlo simulation study, 59
Kato, R., *see* Yamazoe, Y., 707
Kato, R., *see* Yasumori, T., 443
Kauffman, F. C., *see* Belinsky, S. A., 512
Keefer, J. F., *see* Francel, P. C., 34
Kenakin, T. P., and Morgan, P. H. Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists, 214
Killackey, J. J. F., Bonaventura, B. J., Castelano, A. L., Billedeau, R. J., Farmer, W., Deyoung, L., Krantz, A., and Pliura, D. H. A new class of mechanism-based inhibitors of transglutaminase enzymes inhibits the formation of cross-linked envelopes by human malignant keratinocytes, 701
King, C. M., *see* Mattano, S. S., 599
Kleckner, N. W., *see* Verdoorn, T. A., 360
Klein, M., *see* Musacchio, J. M., 1
Krantz, A., *see* Killackey, J. J. F., 701
Kriwacki, R. W. and Makriyannis, A. The conformational analysis of Δ^9 - and $\Delta^{9,11}$ -tetrahydrocannabinols in solution using high resolution nuclear magnetic resonance spectroscopy, 495
Kubow, S. and Wells, P. G. *In vitro* bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase, 504
Kunugi, K., *see* Vazquez-Padua, M. A., 98
Kuo, J. F., *see* Parente, J. E., 26
Kwatra, M. M., Ptasiński, J., and Hosey, M. M. The porcine heart M2 muscarinic receptor: Agonist-induced phosphorylation and comparison of properties with the chick heart receptor, 553
- L**
- Lam, M.-H., *see* Hwang, S.-B., 48
Lamontagne, S., *see* Guillemette, G., 339
Land, S., *see* Mattano, 599
Lazdunski, M., *see* Schmid, A., 766
LeBlanc, G. A., *see* Waxman, D. J., 519
Leid, M., Schimerlik, M. I., and Murray, T. F. Agonist radioligand interactions with the solubilized porcine atrial A₁ adenosine receptor, 450
Lester, R. A. J., Quarum, M. L., Parker, J. D., Weber, E., and Jahr, C. E. Interaction of 6-cyano-7-nitroquinoxaline-2,3-dione with the *N*-methyl-D-aspartate receptor-associated glycine binding site, 565
Levin, W., *see* Hostetler, K. A., 279
Lewin, A. H., de Costa, B. R., Rice, K. C., and Skolnick, P. *meta*- and *para*-isothiocyanato-*t*-butylbicycloorthobenzoate: Irreversible ligands of the γ -aminobutyric acid-regulated chloride inophore, 189
Leysen, J. E., Wynants, J., Eens, A., and Janssen, P. A. J. Ketanserin reduces a particular monoamine pool in peripheral tissues, 375
Liu, X.-F., Yuan, H., Haniu, M., Iyanagi, T., Shively, J. E., and Chen, S. Reaction of rat liver DT-diaphorase (NAD(P)H:Quinone acceptor reductase) with 5'-[*p*-(fluorosulfonyl)benzoyl]-adenosine, 818
Lorenzi, M. V., *see* Potter, L. T., 652
Lorr, N. A., Bloom, S. E., Park, S. S., Gelboin, H. V., Miller, H., and Friedman, F. K. Evidence for a PCN-P450 enzyme in chickens and comparison of its development with that of other phenobarbital-inducible forms, 610
Lotti, V. J., *see* Chang, R. S. L., 803
Loullis, C. C., *see* Hirsch, J. D., 164
Lunetta, J. M., Sugiyama, K., and Correia, M. A. Secobarbital-mediated inactivation of rat liver cytochrome P-450: A mechanistic reappraisal, 10
- M**
- Maayani, S., *see* Zgombick, J. M., 484
Magliozzo, R. S., Peisach, J., and Ciriolo, M. R. Transfer RNA is cleaved by activated bleomycin, 428
Mahle, C. D., *see* Zgombick, J. M., 484
Makriyannis, A., *see* Kriwacki, R. W., 495
Malkowitz, L., *see* Hirsch, J. D., 157, 164
Mamiya, S., *see* Ishikawa, T., 760
Manganiello, V. C., *see* Smith, C. J., 381

- Marks, G. S., *see* Riddick, D. S., 626
 Markstein, R., *see* Seiler, M. P., 643
 Matsuo, H., *see* Haga, K., 286
 Mattano, S. S., Land, S., King, C. M., and Weber, W. W. Purification and biochemical characterization of hepatic arylamine *N*-acetyltransferase from rapid and slow acetylator mice: Identity with arylhydroxamic acid *N,O*-acetyltransferase and *N*-hydroxyarylamine *O*-acetyltransferase, 599
 McHugh, M., *see* Woynarowski, J. M., 177
 McKenna, R., Beveridge, A. J., Jenkins, T. C., Neidle, S., and Denny, W. A. Molecular modelling of DNA-antitumour drug intercalation interactions: Correlation of structural and energetic features with biological properties for a series of phenylquinoline-8-carboxamide compounds, 720
 McKinney, M., Anderson, D., and Vella-Rountree, L. Different agonist-receptor active conformations for rat brain M1 and M2 muscarinic receptors that are separately coupled to two biochemical effector systems, 39
 McLaughlin, J. T. and Hawrot, E. Structural characterization of α -bungarotoxin-binding proteins from *Aplysia californica*, 593
 McQueen, J., and Semple, P. F. Divalent cation-induced interconversion of hepatic angiotensin receptor subtypes, 809
 Mehta, I., *see* Reidy, G. F., 736
 Meloche, S., *see* Féthière, J., 584
 Menozzi, M., *see* Gresh, N., 251
 Michel, M. C., Brodde, O.-E., Schnepel, B., Behrendt, J., Tschada, R., Motulsky, H. J., and Insel, P. A. [3 H]Idazoxan and some other α_2 -adrenergic drugs also bind with high affinity to a nonadrenergic site, 324
 Miller, H., *see* Lorr, N. A., 610
 Miller, R. J., *see* Murphy, S. N., 671
 Minobe, W., *see* Bristow, M. R., 295
 Mitsuhashi, M., and Payan, D. G. Receptor glycosylation regulates the affinity of histamine H1 receptors during smooth muscle cell differentiation, 311
 Mitsuhashi, M., and Payan, D. G. Solubilization and characterization of the pyrilamine-binding protein from cultured smooth muscle cells, 751
 Moerschbaecher, J. M., *see* Gonzalez, R. A., 774
 Molowa, D. T., *see* Hostetler, K. A., 279
 Mong, S., *see* O'Sullivan, B. P., 795
 Moody, E. J., *see* Evoniuk, G., 695
 Mor, A., *see* Amiche M., 774
 Morgan, P. H., *see* Kenakin, T. P., 214
 Morrison, W. J., *see* Shukla, S. D., 409
 Morrissey, J. J., *see* Waxman, D. J., 519
 Motulsky, H. J., *see* Michel, M. C., 324
 Mouillac, B., *see* Guillemette, G., 339
 Murayama, N., *see* Yamazoe, Y., 707
 Murayama, N., *see* Yasumori, T., 443
 Murphy, S. N. and Miller, R. J. Two distinct quisqualate receptors regulate Ca^{2+} homeostasis in hippocampal neurons *in vitro*, 671
 Murray, M., *see* Reidy, G. F., 736
 Murray, T. F., *see* Blair, T. A., 661
 Murray, T. F., *see* Leid, M., 450
 Musacchio, J. M., Klein, M., and Paturzo, J. J. Effects of dextromorphan site ligands and allosteric modifiers on the binding of (+)-[3 H]3-(3-hydroxyphenyl)-*N*-(1-propyl)piperidine, 1
- N
- Nakane, H., *see* Ono, K., 578
 Nakata, H. Affinity chromatography of A₁ adenosine receptors of rat brain membranes, 780
 Neidle, S., *see* McKenna, R., 720
 Neil, A., *see* Karlsson, M. O., 59
 Nestler, E. J., *see* Beitner, D. B., 559
 Nestler, E. J., Terwilliger, R. Z., and Halm, E. Corticosterone increases protein tyrosine kinase activity in the locus coeruleus and other monoaminergic nuclei of rat brain, 265
 Ng, D. S., *see* Parente, J. E., 26
 Nguyen, T. T., *see* Féthière, J., 584
 Nicholson, J. K., *see* Gartland, K. P. R., 242
 Nicolas, P., *see* Amiche M., 774
 Nogi, Y., *see* Yasumori, T., 443
- O
- O'Brien, E. T., Asai, D. J., Jacobs, R. S., and Wilson, L. Selective inhibition of cytokinesis in sea urchin embryos by low concentrations of stypoldione, a marine natural product that reacts with sulfhydryl groups, 635
 Okey, A. B., Vella, L. M., Harper, P. A. Detection and characterization of a low affinity form of cytosolic Ah receptor in livers of mice nonresponsive to induction of cytochrome P₁-450 by 3-methylcholanthrene, 823
 Ong, H., *see* Féthière, J., 584
 Ono, K., Nakane, H., Herdewijn, P., Balzarini, J., and De Clercq, E. Differential inhibitory effects of several pyrimidine 2',3'-dideoxynucleoside 5'-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases, 578
 Orozco, M., Canela, E. I., and Franco, R. Theoretical study of the protonation and tautomerization of adenosine, formycin, and their 2-NH₂ and 2-F derivatives: Functional implications in the mechanism of reaction of adenosine deaminase, 257
 O'Sullivan, B. P., and Mong, S. Binding of radiolabeled high affinity antagonist to leukotriene D₄ receptor in guinea pig lung membranes: Interconversion of agonist-receptor binding affinity states, 795
- P
- Parente, J. E., Walsh, M. P., Girard, P. R., Kuo, J. F., Ng, D. S., and Wong, K. Effects of gold coordination complexes on neutrophil function are mediated via inhibition of protein kinase C, 26
 Parenti, M., *see* Blair, T. A., 661
 Paris, H., Galitzky, J., and Senard, J. M. Interactions of full and partial agonists with HT29 cell α_2 -adrenoceptor: Comparative study of [3 H]UK-14,404 and [3 H]clonidine binding, 345
 Park, S. S., *see* Lorr, N. A., 610
 Park, S. S., *see* Riddick, D. S., 626
 Parker, J. D., *see* Lester, R. A. J., 565
 Pasternak, G. W., *see* Price, M., 67
 Paturzo, J. J., *see* Musacchio, J. M., 1
 Pauwels, R., *see* Balzarini, J., 571
 Payan, D. G., *see* Mitsuhashi, M., 311
 Payan, D. G., *see* Mitsuhashi, M., 751
 Peisach, J., *see* Magliozzo, R. S., 428
 Peter, A. B., *see* Yao, Y., 319
 Phillips, W. J. and Hinkle, P. M. Solubilization and characterization of pituitary thyrotropin-releasing hormone receptors, 533
 Philpot, R. M., *see* Gasser, R., 617
 Pliura, D. H., *see* Killackey, J. J. F., 701
 Politi, P. M., and Sinha, B. K. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: Implications for the mechanisms of drug resistance, 271
 Port, J. D., *see* Bristow, M. R., 295
 Potter, L. T., Ferrendelli, C. A., Hanchett, H. E., Hollifield, M. A., and Lorenzi, M. V. Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors, 652
 Price, M., Gistrack, M. A., Itzhak, Y., Hahn, E. F., and Pasternak, G. W. Receptor binding of [3 H]naloxone benzoylhydrazone: A reversible κ and slowly dissociable μ opiate, 67
 Prozialeck, W. C., *see* Ford, J. M., 105

Ptasienski, J., *see* Kwatra, M. M., 553
Pullman, B., *see* Gresh, N., 251

Q

Quarum, M. L., *see* Lester, R. A. J., 565

R

Rapoport, H., *see* Swanson, K. L., 223
Rasmussen, R., *see* Bristow, M. R., 295
Reidy, G. F., Mehta, I., and Murray, M. Inhibition of oxidative drug metabolism by orphenadrine: *In vitro* and *in vivo* evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics, 736
Reynolds, C. A., *see* Gago, F., 232
Rice, H. L., *see* Joseph, S. K., 355
Rice, K. C., *see* Lewin, A. H., 189
Richards, W. G., *see* Gago, F., 232
Riddick, D. S., Park, S. S., Gelboin, H. V., and Marks, G. S. Effects of a series of 4-Alkyl analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine on the major inducible cytochrome P-450 isozymes of rat liver, 626
Riordan, J. R., *see* Busche, R., 414
Rogawski, M. A. Aminopyridines enhance opening of calcium-activated potassium channels in GH₃ anterior pituitary cells, 458
Roland, R. M., *see* Fisher, S. K., 195
Romey, G., *see* Schmid, A., 766
Roseboom, P. H., and Gnegy, M. E. Acute *in vitro* amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site, 139
Rosegay, A., *see* Chang, R. S. L., 803
Rutledge, A., *see* Wei, X. Y., 541

S

Safe, S., *see* Harris, M., 729
Sagan, S., *see* Amiche M., 774
Sall, D. J., *see* Grunewald, G. L., 93
Sardina, F. J., *see* Swanson, K. L., 223
Schimerlik, M. I., *see* Leid, M., 450
Schmid, A., Romey, G., Barhanin, J., and Lazdunski, M. SR33557, an indolizinsulfone blocker of Ca²⁺ channels: Identification of receptor sites and analysis of its mode of action, 766
Schnepel, B., *see* Michel, M. C., 324
Schols, D., *see* Balzarini, J., 571
Schudt, C., *see* Eveleigh, P., 477
Seidenberg, M., *see* Ellis, J., 173
Seiler, M. P., Markstein, R., Walkinshaw, M. D., and Boelsterli, J. J. Characterization of dopamine receptor subtypes by comparative structure-activity relationships: Dopaminomimetic activities and solid state conformation of monohydroxy-1,2,3,4,4a,5,10,10a-octahydrobenz[*g*]qui nolines and its implications for a rotamer-based dopamine receptor model, 643
Semple, P. F., *see* McQueen, J., 809
Senard, J. M., *see* Paris, H., 345
Shilstone, J., *see* Burstein, S. H., 6
Shively, J. E., *see* Liu, X.-F., 818
Shoshani, I., *see* Johnson, R. A., 681
Shukla, S. D., Morrison, W. J., and Dhar, A. Desensitization of platelet-activating factor-stimulated protein phosphorylation in platelets, 409
Sigal, I. S., *see* Cheung, A. H., 132
Sigel, E., *see* Yao, Y., 319
Sigmund, R. D., *see* Woynarowski, J. M., 177
Silverstone, A. E., *see* Fine, J. S., 18
Sinha, B. K., *see* Politi, P. M., 271

Skolnick, P., *see* Evoniuk, G., 695
Skolnick, P., *see* Lewin, A. H., 189
Smith, C., *see* Johlin, F. C., 745
Smith, C. J., and Manganiello, V. C. Role of hormone-sensitive low K_m cAMP phosphodiesterase in regulation of cAMP-dependent protein kinase and lipolysis in rat adipocytes, 381
Steffey, M. E., *see* Barrett, R. W., 394
Stephens, L. R., *see* Berrie, C. P., 526
Strader, C. D., *see* Cheung, A. H., 132
Stübner, D., *see* Johnson, R. A., 681
Sugiyama, K., *see* Lunetta, J. M., 10
Swain, E., *see* Johlin, F. C., 745
Swanson, K. L., Aracava, Y., Sardina, F. J., Rapoport, H., Aronstam, R. S., and Albuquerque, E. X. *N*-Methylanatoxinol isomers: Derivatives of the agonist (+)-anatoxin-a block the nicotinic acetylcholine receptor ion channel, 223
Szekely, A. M., Barbaccia, M. L., Alho, H., and Costa, E. In primary cultures of cerebellar granule cells the activation of *N*-methyl-D-aspartate-sensitive glutamate receptors induces *c-fos* mRNA expression, 401

T

Taylor, P., *see* Ambler, S. K., 369
Tephly, T. R., *see* Johlin, F. C., 745
Terwilliger, R. Z., *see* Nestler, E. J., 265
Thomas, J. M., and Hoffman, B. B. Chronic somatostatin treatment induces enhanced forskolin-stimulated cAMP accumulation in wild-type S49 mouse lymphoma cells but not in protein kinase-deficient mutants, 116
Thomas, P. E., *see* Hostetler, K. A., 279
Thurman, R. G., *see* Belinsky, S. A., 512
Tonani, R., *see* Gresh, N., 251
Trenti, T., *see* De Matteis, F., 831
Triggle, D. J., *see* Wei, X. Y., 541
Tschada, R., *see* Michel, M. C., 324
Tümmeler, B., *see* Busche, R., 414

U

Uchiyama, H. *see* Haga, K., 286

V

Van Aerschot, A., *see* Balzarini, J., 571
Vazquez-Padua, M. A., Kunugi, K., and Fischer, P. H. Enzyme regulatory site-directed drugs: Study of the interactions of 5'-amino-2', 5'-dideoxythymidine (5'-adThd) and thymidine triphosphate with thymidine kinase and the relationship to the stimulation of thymidine uptake by 5'-adThd in 647V cells, 98
Vella, L. M., *see* Okey, A. B., 823
Vella-Rountree, L., *see* McKinney, M., 39
Verdoorn, T. A., Kleckner, N. W., and Dingledine, R. *N*-methyl-D-aspartate/glycine and quisqualate/kainate receptors expressed in *Xenopus* oocytes: Antagonist pharmacology, 360

W

Walkinshaw, M. D., *see* Seiler, M. P., 643
Walsh, M. P., *see* Parente, J. E., 26
Waszczak, B. L., *see* Cox, R. F., 125
Waxman, D. J., Morrissey, J. J., and LeBlanc, G. A. Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver: Pituitary control of hepatic NADPH cytochrome P-450 reductase, 519
Weber, E., *see* Lester, R. A. J., 565
Weber, W. W., *see* Mattano, S. S., 599
Wei, X. Y., Rutledge, A., and Triggle, D. J. Voltage-dependent binding of 1,4-dihydropyridine Ca²⁺ channel antagonists and activators in cultured neonatal rat: Ventricular myocytes, 541

Weinstein, H. *see* Gannon, M. N., 205

Wells, P. G., *see* Kubow, S., 504

Wilson, L., *see* O'Brien, E. T., 635

Wise, B., *see* Grunewald, G. L., 93

Wolfram, C. A. W., *see* Barrett, R. W., 394

Wong, K., *see* Parente, J. E., 26

Woynarowski, J. M., McHugh, M., Sigmund, R. D., and Beerman, T.
A. Modulation of topoisomerase II catalytic activity by DNA minor
groove binding agents distamycin, Hoechst 33258, and 4',6-diam-
idine-2-phenylindole, 177

Wrighton, S. A., *see* Hostetler, K. A., 279

Wu, C.-S. C., and Yang, J. T. Tacrine protection of acetylcholinesterase
from inactivation by diisopropylfluorophosphate: A circular dichro-
ism study, 85

Wynants, J., *see* Leysen, J. E., 375

Y

Yamazoe, Y., Gong, D., Murayama, N., Abu-Zeid, M., and Kato, R.
Regulation of hepatic cortisol sulfotransferase in rats by pituitary
growth hormone, 707

Yamazoe, Y., *see* Yasumori, T., 443

Yang, J. T., *see* Wu, C.-S. C., 85

Yao, Y., Peter, A. B., Baur, R., and Sigel, E. The tremorigen aflatrem
is a positive allosteric modulator of the γ -aminobutyric acid_A
receptor channel expressed in *Xenopus* oocytes, 319

Yasumori, T., Murayama, N., Yamazoe, Y., Abe, A., Nogi, Y., Fuka-
sawa, T., and Kato, R. Expression of a human P-450IIC gene in
yeast cells using galactose-inducible expression system, 443

Ye, Q., *see* Grunewald, G. L., 93

Yeung, S.-M. H., *see* Johnson, R. A., 681

Yuan, H., *see* Liu, X.-F., 818

Z

Zacharewski, T., *see* Harris, M., 729

Zgombick, J. M., Beck, S. G., Mahle, C. D., Craddock-Royal, B., and
Maayani, S. Pertussis toxin-sensitive guanine nucleotide-binding
protein(s) couple adenosine A₁ and 5-hydroxytryptamine_{1A} recep-
tors to the same effector systems in rat hippocampus: Biochemical
and electrophysiological studies, 484

Zukin, S. R., *see* Javitt, D. C., 387

SUBJECT INDEX FOR VOLUME 35

A

- Acetylcholine, α -bungarotoxin-binding proteins, structural characterization (*Aplysia californica*), 593
- Acetylcholinesterase, tacrine protection from inactivation, diisopropyl-fluorophosphate, 85
- Acquired immune deficiency syndrome
differential inhibitory effects, pyrimidine 2',3'-dideoxynucleoside 5'-triphosphates, 578
5-halogeno-3'-fluoro-2',3'-dideoxyuridines, inhibitors of HIV, 571
- Actinomycin D, gene expression, inducible hybrid viral gene, model, 433
- Acylation agents, *meta*- and *para*-isothiocyanato-*t*-butylbicycloorthobenzoate, GABA-regulated chloride ionophore (rat), 189
- Adenocarcinoma, full and partial agonist interactions, α -2 adrenoreceptors, 345
- Adenosine, analog sensitivity, embryonic heart (chick), 661
- Adenosine deaminase, theoretical study, protonation, tautomerization, 257
- Adenylate cyclase
decrease, morphine action, locus coeruleus (rat), 559
desensitization of dopamine receptor activities, amphetamine, 139
P site-mediated inhibition, cation and structural requirements, 681
sensitivity to magnesium, β adrenoreceptors, lymphocytes, 304
stimulation, β adrenoreceptors, myocardium (human), 295
- Adenylyl cyclase, sensitivity to adenosine analogs, embryonic heart (chick), 661
- Adipocytes, regulation of lipolysis, role, hormone-sensitive cAMP phosphodiesterase (rat), 381
- Adrenal cortex, heparin effects, 1,4,5-trisphosphate binding (bovine), 339
- Adrenoceptors
 α , morphine action, locus coeruleus (rat), 559
 α -2
agonist interactions, HT29 cells, 345
idazoxan high affinity binding, nonadrenergic site (rat), 324
 β
adenylate cyclase sensitivity, magnesium, 304
adenylate cyclase stimulation, ventricular myocardium (human), 295
- Aflatoxin, GABA_A receptor channel modifier, *Xenopus* oocytes, 319
- Agonists, relative potency, single and multiple transducer receptor coupling, 214
- 5'-Amino-2',5'-dideoxythymidine, mechanism of action, 98
- γ -Aminobutyric acid
benzodiazepine-linked chloride ionophore, disruption, ultraviolet irradiation (rat), 695
GABA_A, benzodiazepine, transmembrane topology, 75
-regulated chloride ionophore, irreversible ligands (rat), 189
- Aminopyridines, opening of calcium-activated potassium channels, GH₃ anterior pituitary cells, 458
- Amphetamine, desensitization of dopamine receptor activities, agonist binding, 139
- Angiotensin, receptor subtypes, divalent cation-induced interconversion (rat), 809
- Anthracycline
intercalating derivatives, comparative DNA binding affinities, 251
radioiodinated analogue of daunomycin, preparation and utility, multidrug resistance, 414
- Anticonvulsants, dextromethorphan site ligands, 3-(3-hydroxyphenyl)-*N*-(1-propyl)piperidine binding (guinea pig), 1

- Antimycotic agents, imidazole, coinduction, hepatic cytochrome P-450 (rat), 279
- Antitumor activity, DNA-antitumor drug intercalation interactions, molecular modeling, 720
- Arylamine *N*-acetyltransferase, purification and biochemical characterization, rapid and slow acetylators mice, 599
- Aryl hydrocarbon hydroxylase, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-mediated induction, partial antagonism, 6-methyl-1,3,8-trichlorodibenzofuran (rat), 729
- Aspergillus flavus*, tremorigen aflatoxin, GABA_A receptor channel modifier, *Xenopus* oocytes, 319
- Atrial natriuretic factor, receptor subpopulations, epithelial and fibroblast cell lines, 584
- Auranofin, gold coordination complexes, neutrophil function, protein kinase C inhibition (human), 26
- Azidothymidine triphosphate, differential inhibitory effects, pyrimidine 2',3'-dideoxynucleoside 5'-triphosphates, cellular DNA polymerases, 578

B

- Benzodiazepine, chloride ionophore, disruption, ultraviolet irradiation (rat), 695
- Bilirubin, -degrading system, microsomal fraction, liver (rat), 831
- Bleomycin
activated, cleavage, transfer RNA, 428
gene expression, inducible hybrid viral gene, model, 433
- Bombesin, gastrin-releasing peptide receptor, brain membranes (rat), 689
- Bradykinin analogs, effect of antagonists, sensory neuronal cell line, 34
- Brain
A, adenosine receptors, affinity chromatography (rat), 780
agonist-receptor active conformations, muscarinic receptor subtypes (rat), 39
characterization of L-365,260 binding (guinea pig), 803
membranes, gastrin-releasing peptide receptor (rat), 689
neurons, intracellular pool, GABA_A/benzodiazepine receptors, 183
protein tyrosine kinase activity, corticosterone (rat), 265
P site-mediated inhibition of adenylate cyclase, cation and structural requirements, 681
reduction of monoamine pools, ketanserin, peripheral tissues (rat), 375
- Breast cancer, VP-16 uptake, mechanisms of drug resistance (human), 271
- α -Bungarotoxin, binding proteins, structural characterization (*Aplysia californica*), 593
- t*-Butylbicycloorthobenzoate, irreversible ligands, GABA-regulated chloride ionophore (rat), 189

C

- Calcium
-activated potassium channels, aminopyridines, GH₃ anterior pituitary cells, 458
cytoplasmic concentrations, muscarinic receptors, neuroblastoma cells, 195
effect of bradykinin antagonists, neuronal cell line, 34
heparin effects, inositol 1,4,5-trisphosphate binding, bovine adrenal cortex, 339
homeostasis, quisqualate receptors, hippocampal neurons (mouse), 671

- Calcium—continued
 nonmitochondrial sequestered, release from muscle cells, 369
 release in brain microsomes, inositol trisphosphate receptor density (rat), 355
- Calcium channel
 1,4-dihydropyridine antagonists, voltage-dependent binding, ventricular myocytes (rat), 541
 indolizinsulfone blocker SR33557, receptor site identification (rabbit), 766
- Calmodulin antagonists, phenothiazines and related drugs, multidrug resistance, 105
- Cannabinols, conformational analysis of tetrahydrocannabinols, high resolution NMR, 495
- Carbachol, -stimulated phosphoinositide hydrolysis, phencyclidine recognition, NMDA inhibition (rat), 787
- Catalepsy, tetrahydrocannabinol-induced, immunization against prostaglandins (mouse), 6
- Cerebellum, calcium release in brain microsomes, inositol trisphosphate receptor density (rat), 355
- Cerebrum, interaction of muscarinic acetylcholine receptors, G protein (pig), 286
- Chloride ionophore
 disruption, ultraviolet irradiation (rat), 695
 GABA-regulated, irreversible ligands (rat), 189
- CHO cells, antagonist binding properties, cloned muscarinic receptors, 469
- Cholecystokinin, characterization of L-365,260 binding (guinea pig), 803
- Chromatography, affinity, A₁ adenosine receptors, brain membranes (rat), 780
- Clonidine
 -displacing substance, idazoxan, binding to nonadrenergic site (rat), 324
 full and partial agonist interactions, α -2 adrenoceptors, HT29 cells, 345
 novel action of morphine, locus coeruleus (rat), 559
- Clotriazole, imidazole antimycotic agents, coinduction, hepatic cytochrome P-450 (rat), 279
- Colonic neoplasms, modulation of 5-fluoro-2'-deoxyuridine response, folinic acid, thymidylate synthase (human), 422
- Corticosterone, protein tyrosine kinase activity, locus coeruleus (rat), 265
- Cortisol sulfotransferase, hepatic, regulation, pituitary growth hormone (rat), 707
- 6-Cyano-7-nitroquinoxaline-2,3-dione, interaction with glycine binding site, NMDA receptor, 565
- Cyclic AMP
 chronic somatostatin treatment and withdrawal, S49 cells, 116
 metactoid sensitization model, multiple receptors (guinea pig), 205
- Cyclic AMP phosphodiesterase, hormone-sensitive, regulation, lipolysis in adipocytes (rat), 381
- Cyclic GMP, effect of bradykinin antagonists, neuronal cell line, 34
- Cytochrome P-450
 alteration of protein levels by hypophysectomy, enzyme activities, liver (rat), 519
 coinduction of multiple proteins, imidazole antimycotic agents (rat), 279
 evidence for PCN-P450 enzyme (chicken), 610
 inhibition of oxidative drug metabolism, orphenadrine, 736
 major inducible isozymes, 4-alkyl analogues, 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine (rat), 626
 primary structure of isozyme 5, lung and liver expression (rabbit, rat), 617
- Cytochrome P₁-450, cytosolic Ah receptor, low affinity form (mouse), 823
- Cytochrome P-450_u, secobarbital-mediated inactivation (rat), 10
- Cytochrome P-450IIC, human gene expression in yeast cells, galactose-inducible expression system, 443
- Cytokinesis, selective inhibition, low stypoldione, embryo (sea urchin), 635
- D**
- Daunomycin, radioiodinated analogue of, preparation and utility, multidrug resistance, 414
- Daunorubicin, VP-16 uptake, mechanisms of drug resistance (human), 271
- Dermenkephalin, specific agonist for δ opioid receptor, 774
- Dexamethasone
 evidence for PCN-P450 enzyme (chicken), 610
 imidazole antimycotic agents, coinduction, hepatic cytochrome P-450 (rat), 279
- Dextromethorphan, effects of site ligands, 3-(3-hydroxyphenyl)-N-(1-propyl)piperidine binding (guinea pig), 1
- 4',6-Diamidine-2-phenylindole, modulation, topoisomerase II catalytic activity, 177
- 2',5'-Dideoxy-adenosine, P site-mediated inhibition of adenylate cyclase, cation and structural requirements, 681
- 3,5-Diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine, effects of 4-alkyl analogues, cytochrome P-450 isozymes, liver (rat), 626
- 1,4-Dihydropyridine, calcium channel antagonists, voltage-dependent binding, ventricular myocytes (rat), 541
- Diisopropylfluorophosphate, tacrine protection of acetylcholinesterase, inactivation, 85
- Distamycin, modulation, topoisomerase II catalytic activity, 177
- Distamycin A, binding to alternating DNA sequences, 232
- DNA
 alternating sequences, nonintercalative drug binding, 232
 -antitumor drug intercalation interactions, molecular modeling, 720
 comparative binding affinities, intercalating anthracycline derivatives, 251
 minor groove binding agents, modulation, topoisomerase II catalytic activity, 177
- DNA polymerase, differential inhibitory effects, pyrimidine 2',3'-dideoxynucleoside 5'-triphosphates, 578
- Dopamine
 desensitization of receptor activities, amphetamine, 139
 receptor reserve, N-n-propylnorapomorphine enantiomers, 125
 rotamer-based receptor model, 643
- Dorsal root ganglion, effect of bradykinin antagonists, neuronal cell line, 34
- Doxorubicin, multidrug resistance, phenothiazines, related drugs, 105
- Drug resistance, etoposide uptake in tumor cells (human), 271
- DT-diaphorase, reaction with 5'-[p-(fluorosulfonyl)benzoyl]-adenosine, liver (rat), 818
- E**
- Epidermal growth factor, -regulated protein kinases, synthetic peptide substrates, PC12 cells, 331
- Epithelial cells
 atrial natriuretic factor receptor subpopulations, 584
 thymic, specific binding protein, 2,3,7,8-tetrachlorodibenzo-p-dioxin (human), 713
- Erythrocytes, phosphatidylinositol 4,5-bisphosphate hydrolysis, purinergic stimulation (turkey), 526
- N-Ethoxycarbonyl-2-ethoxy-1-2-dihydroquinoline, differences in dopamine receptor reserve, N-n-propylnorapomorphine enantiomers, 125
- 7-Ethoxycoumarin, glycolysis and mixed function oxidation, liver (rat), 512
- Etoposide, differential drug uptake, mechanisms, drug resistance (human), 271
- F**
- Fibroblasts, atrial natriuretic factor receptor subpopulations, 584
- 5-Fluoro-2'-deoxyuridine, modulation of response, folinic acid, colonic

- tumor cell lines (human), 422
 5'-[p-(Fluorosulfonyl)benzoyl]-adenosine, reaction with liver DT-diaphorase (rat), 818
trans-Flupenthixol, phenothiazines and related drugs, multidrug resistance, 105
 Folinic acid, modulation of 5-fluoro-2'-deoxyuridine response, colonic tumor cell lines, thymidylate synthase (human), 422
 Formycin, protonation and tautomerization, adenosine deaminase, 257
 10-Formyltetrahydrofolate dehydrogenase, mechanism of methanol poisoning, liver (rat, human), 745
 Forskolin, chronic somatostatin treatment and withdrawal, S49 cells, 116

G

- Galactose, -inducible expression system, human P-450IIC gene expression, yeast cells, 443
 Gallamine, biphasic allosteric effects, muscarinic receptors, 173
 Gastrin, -releasing peptide receptor, brain membranes (rat), 689
 Gene, expression, inducible hybrid viral gene, model, 433
 Glucocorticoids
 corticosterone, protein tyrosine kinase activity, brain (rat), 265
 gene expression, inducible hybrid viral gene, model, 433
 Glutamate, biexponential kinetics of MK-801, NMDA receptor channels (rat), 387
 Glycine
 biexponential kinetics of MK-801, NMDA receptor channels (rat), 387
 binding site, 6-cyano-7-nitroquinoxaline-2,3-dione, NMDA receptor, 565
 N-methyl-D-aspartate, receptor antagonist pharmacology, *Xenopus* oocytes, 360
 Glycolysis, mixed function oxidation and, 7-ethoxycoumarin, liver (rat), 512
 Glycosylation, affinity of histamine H1 receptors, smooth muscle cell differentiation, 311
 Gold, coordination complexes, neutrophil function, protein kinase C inhibition (human), 26
 G protein
 adenosine A₁ receptor, agonist radioligand interactions (pig), 450
 agonist-promoted sequestration, β_2 -adrenergic receptors, 132
 cholecystokinin type-A receptors, CHP212 neuroblastoma cells, 394
 coupling, relative potency, agonists, 214
 interaction with muscarinic acetylcholine receptors, cerebrum (pig), 286
 novel action of morphine, locus coeruleus (rat), 559
 Granule cells, cerebellar, activation, NMDA-sensitive glutamate receptors (rat), 401
 Growth hormone
 alteration of P-450 protein levels, hypophysectomy, liver (rat), 519
 pituitary, regulation, hepatic cortisol sulfotransferase (rat), 707

H

- 5-Halogeno-3'-fluoro-2',3'-dideoxyuridine, inhibitor of HIV, 571
 Haloperidol, dextromethorphan site ligands, 3-(3-hydroxyphenyl)-*N*-(1-propyl)piperidine binding (guinea pig), 1
 Heart
 adenosine A₁ receptor, agonist radioligand interactions (pig), 450
 embryonic, sensitivity, adenosine analogs (chick), 661
 M2 muscarinic receptor, agonist-induced phosphorylation (chick), 553
 nonfailing and failing ventricular myocardium, adenylate cyclase stimulation, β 2 adrenoceptors (human), 295
 Heparin
 effects on inositol 1,4,5-trisphosphate binding, calcium release, bovine adrenal cortex, 339
 inositol trisphosphate receptor density, calcium release, brain microsomes (rat), 355

- Hippocampus
 calcium homeostasis in neurons, quisqualate receptors (mouse), 671
 M1 muscarinic receptors, tetrahydroaminoacridine, other allosteric antagonists, 652
 pertussis toxin-sensitive G proteins, adenosine A₁ and 5-HT_{1A} receptors (rat), 484
 HL-60 cells, mechanisms of drug resistance, VP-16 uptake (human), 271
 Hoechst 33258, modulation, topoisomerase II catalytic activity, 177
 Horseradish peroxidase, bioactivation of phenytoin, 504
 HT29 cells, full and partial agonist interactions, α -2 adrenoceptors, 345
 Human immunodeficiency virus, 5-halogeno-3'-fluoro-2',3'-dideoxyuridines, inhibitors, 571
N-Hydroxyarylamine *O*-acetyltransferase, purification of hepatic arylamine *N*-acetyltransferase, rapid and slow acetylator mice, 599
 3-(3-Hydroxyphenyl)-*N*-(1-propyl)piperidine, binding of, effects, dextromethorphan site ligands (guinea pig), 1
 Hypophysectomy, alteration of P-450 protein levels, enzyme activities, liver (rat), 519

I

- Idazoxan, high affinity binding, nonadrenergic site (rat), 324
 Imidazole, antimycotic agents, coinduction, hepatic cytochrome P-450 (rat), 279
 Indolizinosulfones, SR33557, receptor site identification (rabbit), 766
 Inositol 1,4,5-trisphosphate, release of nonmitochondrial sequestered calcium, permeabilized muscle cells, 369
 Inositol triphosphate
 effect of bradykinin antagonists, neuronal cell line, 34
 receptor density, calcium release, brain microsomes (rat), 355
 Insulin, regulation of lipolysis in adipocytes, role, hormone-sensitive cAMP phosphodiesterase (rat), 381
 Ionophores
 chloride, disruption, ultraviolet irradiation (rat), 695
 mechanism-based inhibitors, transglutaminase enzymes, malignant keratinocytes (human), 701
 Irradiation, ultraviolet, disruption, GABA/benzodiazepine receptor-linked chloride ionophore (rat), 695
para-Isothiocyanato-*t*-butylbicycloorthobenzoate, irreversible chloride channel ligands (rat), 189

K

- Kainate, quisqualate, receptor antagonist pharmacology, *Xenopus* oocytes, 360
 Keratinocytes, malignant, mechanism-based inhibitors, transglutaminase enzymes (human), 701
 Ketanserin, monoamine pool reduction, peripheral tissues (rat), 375
 Ketoconazole, imidazole antimycotic agents, coinduction, hepatic cytochrome P-450 (rat), 279
 Kidney, high affinity binding of idazoxan, nonadrenergic site (rat), 324

L

- L-365,260, characterization of binding (guinea pig), 803
 L-659,989, platelet-activating factor, multiple conformational states (rabbit), 48
 Leukemia, VP-16 uptake, mechanisms of drug resistance (human), 271
 Leukotriene D₄, receptor, high affinity antagonist, lung membranes (guinea pig), 795
 Ligands
 binding to mitochondrial benzodiazepine receptors, 164
 dextromethorphan, 3-(3-hydroxyphenyl)-*N*-(1-propyl)piperidine binding (guinea pig), 1
 estimation of binding parameters, Monte Carlo simulation study, 59
 Lipolysis, role of hormone-sensitive cAMP phosphodiesterase, adipocytes (rat), 381

Liver

- angiotensin receptor subtypes, divalent cation-induced interconversion (rat), 809
- cytochrome P-450, inactivation by secobarbital (rat), 10
- cytosolic Ah receptor, low affinity form (mouse), 823
- DT-diaphorase reaction, 5'-[p-(fluorosulfonyl)benzoyl]-adenosine (rat), 818
- glycolysis and mixed function oxidation, 7-ethoxycoumarin (rat), 512
- inactivation of 17 β -substituted steroids, cytochrome P-450, progesterone 21-hydroxylation, 148
- major inducible cytochrome P-450 isozymes, 4-alkyl analogues, 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine (rat), 626
- mechanism of methanol poisoning (rat, human), 745
- microsomal fraction, inducible bilirubin-degrading system (rat), 831
- primary structure, cytochrome P-450 isozyme 5 (rabbit, rat), 617
- purification of arylamine *N*-acetyltransferase, rapid and slow acetylase mice, 599
- regulation of cortisol sulfotransferase, pituitary growth hormone (rat), 707

Locus coeruleus

- increased protein tyrosine kinase activity, corticosterone (rat), 265
- novel action of morphine, adenylate cyclase decrease (rat), 559

Lung

- high affinity antagonist, leukotriene D₄ receptor (guinea pig), 795
- primary structure, cytochrome P-450 isozyme 5 (rabbit, rat), 617

Lymphocytes

- adenylate cyclase sensitivity to magnesium, *beta* adrenoceptors, 304
- stem cell alterations, perinatal exposure, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (mouse), 18

Lymphoma cells, chronic somatostatin treatment and withdrawal, S49 cells, 116

M

Magnesium, sensitivity of adenylate cyclase, *beta* adrenoceptors, 304

Mathematical models, single and multiple transducer receptor coupling, relative potency, agonists, 214

MCF-7 cells

- mechanisms of drug resistance, VP-16 uptake (human), 271
- multidrug resistance, phenothiazines, related drugs, 105

Methanol, mechanism of poisoning, comparison, liver (rat, human), 745

6-Methyl-1,3,8-trichlorodibenzofuran, partial antagonism, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, aryl hydrocarbon hydroxylase induction (rat), 729*N*-Methylatropine isomers, nicotinic acetylcholine receptor ion channel, 223*N*-Methyl-D-aspartate

- glycine, receptor antagonist pharmacology, *Xenopus* oocytes, 360
- inhibition of phosphoinositide hydrolysis, phencyclidine recognition site (rat), 787
- sensitive glutamate receptors, *c-fos* expression, cerebellar granule cells (rat), 401

3-Methylcholanthrene, cytosolic Ah receptor, low affinity form (mouse), 823

Miconazole, imidazole antimycotic agents, coinduction, hepatic cytochrome P-450 (rat), 279

Microsomes

- brain, calcium release, inositol trisphosphate receptor density (rat), 355
- inducible bilirubin-degrading system (rat), 831

Mitochondria

- benzodiazepine receptors, inhibition, respiratory control, 157
- glycolysis and mixed function oxidation, 7-ethoxycoumarin, liver (rat), 512
- ligand binding, benzodiazepine receptors, 164

Mixed function oxidase, glycolysis and, 7-ethoxycoumarin, liver (rat), 512

MK-801, biexponential kinetics of binding, closed and open NMDA receptor channels (rat), 387

Molybdate, binding protein for 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, thymic epithelial cells (human), 713

Monoamines, reduction of pool in peripheral tissues, ketanserin (rat), 375

Monohydroxy-1,2,3,4,4 α ,5,10,10 α -octahydrobenz[*g*]quinolines, rotamer-based dopamine receptor model, 643

Monte Carlo simulation, estimation, ligand binding parameters, 59

Morphine

- novel action in locus coeruleus, adenylate cyclase decrease (rat), 559
- receptor binding, naloxone benzoylhydrazone, 67

Multidrug resistance

- preparation and utility, radioiodinated analogue, daunomycin, 414
- structural features determining activity, phenothiazines, related drugs, 105

Muscle, smooth

- differentiation, receptor glycosylation, histamine H1 receptors, 311
- solubilization and characterization, pyrilamine-binding protein, 751
- vascular, interaction, thyroid hormones (rabbit), 760

Muscle cells, permeabilized, release, nonmitochondrial sequestered calcium, 369

Mutagenesis, agonist-promoted sequestration, β_2 -adrenergic receptors, 132Mycotoxin, tremorigen aflatoxin, GABA_A receptor channel modifier, *Xenopus* oocytes, 319Myocardium, adenylate cyclase stimulation, *beta* adrenoceptors (human), 295

Myocytes, ventricular, voltage-dependent binding, 1,4-dihydropyridine calcium channel antagonists (rat), 541

N

NADPH cytochrome P-450 reductase, alteration of P-450 protein levels, hypophysectomy, liver (rat), 519

Naloxone benzoylhydrazone, receptor binding, 67

 β -Naphthoflavone, glycolysis and mixed function oxidation, 7-ethoxycoumarin, liver (rat), 512

Neocarcinostatin, gene expression, inducible hybrid viral gene, model, 433

Nephrotoxins, region-specific, biochemical effects (rat), 242

Nerve growth factor, -regulated protein kinases, synthetic peptide substrates, PC12 cells, 331

Netropsin, binding to alternating DNA sequences, 232

Neuroblastoma

- cholecystokinin type-A receptors, G protein association, 394
- muscarinic receptor regulation, cytoplasmic calcium concentrations, 195

Neurons

- brain, intracellular pool, GABA_A/benzodiazepine receptors, 183
- hippocampal, calcium homeostasis, quisqualate receptors (mouse), 671
- monoaminergic, protein tyrosine kinase activity, brain (rat), 265

Neutrophils, effect of gold coordination complexes, protein kinase C inhibition (human), 26

Nuclear magnetic resonance spectroscopy

- biochemical effects, region-specific nephrotoxins (rat), 242
- high resolution, conformational analysis, tetrahydrocannabinols, 495

O

Oocytes

Xenopus

- GABA_A receptor channel modifier, tremorigen aflatoxin, 319
- NMDA/glycine, receptor antagonist pharmacology, 360

Opiate, receptor binding, naloxone benzoylhydrazone, 67

Orphenadrine, inhibition of oxidative drug metabolism, 736

P

- PC12 cells, synthetic peptide substrates, regulation, nerve growth factor and epidermal growth factor, 331
- Pertussis toxin, -sensitive guanine nucleotide-binding proteins, adenosine A₁ and 5-HT_{1A} receptors (rat), 484
- P-glycoprotein, radioiodinated analogue of daunomycin, preparation and utility, multidrug resistance, 414
- Phencyclidine, recognition site, NMDA inhibition, phosphoinositide hydrolysis (rat), 787
- Phenobarbital, evidence for PCN-P450 enzyme (chicken), 610
- Phenothiazines, structural features determining activity, cell growth inhibition, multidrug resistance, 105
- Phenylethanolamine, phenylethylamine analogues and, conformational and steric aspects, substrates, 93
- Phenylquinoline-8-carboxamide compounds, DNA-antitumor drug intercalation interactions, molecular modeling, 720
- Phenytion
 bioactivation to reactive free radical intermediate, prostaglandin synthetase, horseradish and thyroid peroxidases, 504
 dextromethorphan site ligands, 3-(3-hydroxyphenyl)-N-(1-propyl)piperidine binding (guinea pig), 1
- Phosphatidylinositol 4,5-bisphosphate, hydrolysis in erythrocytes, purinergic stimulation (turkey), 526
- Phosphoinositide
 hydrolysis, cholecystokinin type-A receptors, G protein association, 394
 hydrolysis in cortical slices, phencyclidine recognition site, NMDA inhibition (rat), 787
- Phospholipase C
 cytoplasmic calcium concentrations, muscarinic receptors, neuroblastoma cells, 195
 PAF-stimulated protein phosphorylation, desensitization, platelets (rabbit), 409
- Phosphorylation, agonist-induced, M2 muscarinic receptor, heart (chick), 553
- Picrotoxin, irreversible chloride channel ligands (rat), 189
- Pirenzepine, agonist-receptor active conformations, muscarinic receptor subtypes (rat), 39
- Pituitary
 alteration of P-450 protein levels, hypophysectomy, liver (rat), 519
 GH₃ anterior, aminopyridines, calcium-activated potassium channel, 458
 growth hormone, regulation, hepatic cortisol sulfotransferase (rat), 707
 solubilization, thyrotropin-releasing hormone receptors (rat), 533
- Platelet-activating factor
 receptors, multiple conformational states (rabbit), 48
 -stimulated protein phosphorylation, desensitization, platelets (rabbit), 409
- Platelets, P site-mediated inhibition of adenylate cyclase, cation and structural requirements, 681
- Potassium channel
 calcium-activated, aminopyridines, GH₃ anterior pituitary cells, 458
 pertussis toxin-sensitive G proteins, adenosine A₁ and 5-HT_{1A} receptors (rat), 484
- Pregnenolone-16- α -carbonitrile-P450 enzyme, comparison with other phenobarbital-inducible forms, development (chicken), 610
- Progesterone hydroxylase, inactivation of 17 β -substituted steroids, cytochrome P-450, 148
- N-n-Propylnorapomorphine, enantiomers, differences, dopamine receptor reserve, 125
- Prostaglandins, immunization, tetrahydrocannabinol-induced catalepsy (mouse), 6
- Prostaglandin synthetase, bioactivation of phenytion, 504
- Protein, platelet-activating factor-stimulated phosphorylation, desensitization, platelets (rabbit), 409
- Protein kinase

- regulation in PC12 cells, nerve growth factor, epidermal growth factor, 331
- regulation of lipolysis in adipocytes, role, hormone-sensitive cAMP phosphodiesterase (rat), 381
- Protein kinase C
 inhibition, gold coordination complexes, neutrophil function (human), 26
 interaction of muscarinic acetylcholine receptors, G protein, cerebrum (pig), 286
- Protein tyrosine kinase, increased activity, corticosterone, locus coeruleus (rat), 265
- Proto-oncogene, c-fos, NMDA-sensitive glutamate receptors, cerebellar granule cells (rat), 401
- Pyrimidine, -binding protein, solubilization, smooth muscle cells, 751
- Pyrimidine 2',3'-dideoxynucleoside 5'-triphosphates, differential inhibitory effects, reverse transcriptase, cellular DNA polymerases, 578

Q

- Quisqualate
 kainate, receptor antagonist pharmacology, *Xenopus* oocytes, 360
 two distinct receptors, calcium homeostasis, hippocampal neurons (mouse), 671

R

- Radioligands
 agonist, interactions, adenosine A₁ receptor (pig), 450
 characterization of L-365,260 binding (guinea pig), 803
- Receptors
 adenosine A₁
 affinity chromatography, brain membranes (rat), 780
 agonist radioligand interactions (pig), 450
 pertussis toxin-sensitive G proteins, hippocampus (rat), 484
 sensitivity, embryonic heart (chick), 661
 β_2 -adrenergic, agonist-promoted sequestration, 132
 Ah, low affinity form, liver (mouse), 823
 angiotensin, divalent cation-induced interconversion (rat), 809
 atrial natriuretic factor, epithelial and fibroblast cell lines, 584
 benzodiazepine
 inhibition, mitochondrial respiratory control, 157
 ligand binding, mitochondria, 164
 cholecystokinin type-A, CHP212 neuroblastoma cells, G protein association, 394
 dopamine, rotamer-based receptor model, 643
 dopamine reserve, N-n-propylnorapomorphine enantiomers, 125
 GABA_A, tremorgen aflatrem, positive allosteric modulator in *Xenopus* oocytes, 319
 GABA_A/benzodiazepine
 intracellular pool, brain neurons, 183
 transmembrane topology, 75
 gastrin, L-365,260 binding (guinea pig), 803
 gastrin-releasing peptide, brain membranes (rat), 689
 glutamate, NMDA sensitivity and c-fos, cerebellar granule cells (rat), 401
 G-protein coupling, 214
 histamine, metactoid sensitization model (guinea pig), 205
 histamine H1
 glycosylation, smooth muscle differentiation, 311
 pyrimidine-binding protein, smooth muscle cells, 751
 5-HT_{1A}, pertussis toxin-sensitive G proteins, hippocampus (rat), 484
 inositol trisphosphate, density and calcium release, brain microsomes (rat), 355
 leukotriene D₄, high affinity antagonist, lung membranes (guinea pig), 795
 N-methyl-D-aspartate
 antagonist pharmacology, *Xenopus* oocytes, 360
 biexponential kinetics, MK-801 (rat), 387

Receptors—continued

- 6-cyano-7-nitroquinoxaline-2,3-dione, glycine binding site, 565
 multiple, metactoid sensitization model (guinea pig), 205
 muscarinic
 agonist-receptor active conformations, brain (rat), 39
 antagonist binding properties, CHO-K1 cells, 469
 calcium concentrations, neuroblastoma cells, 195
 gallamine, biphasic allosteric effects, 173
 interaction, telenzepine enantiomers (rat), 477
 muscarinic acetylcholine, G protein interaction, cerebrum (pig), 286
 muscarinic M1, tetrahydroaminoacridine, hippocampus, 652
 muscarinic M2, agonist-induced phosphorylation, heart (chick), 553
 nalozone benzoylhydrazone, binding, 67
 nicotinic acetylcholine, blockade, *N*-methylanatoxinol isomers, 223
 opioid δ , specific agonist, dermenkephalin, 774
 phencyclidine, NMDA receptor channels, MK-801 kinetics (rat), 387
 platelet-activating factor, multiple conformational states (rabbit), 48
 purinergic, phosphatidylinositol 4,5-bisphosphate hydrolysis (turkey), 526
 quisqualate, calcium homeostasis, hippocampal neurons (mouse), 671
 thyrotropin-releasing hormone, solubilization, pituitary (rat), 533
 RNA, transfer, cleavage, activated bleomycin, 428
 RNA, messenger
 imidazole antimycotic agents, coinduction, hepatic cytochrome P-450 (rat), 279
 NMDA-sensitive glutamate receptors, *c-fos* expression, cerebellar granule cells (rat), 401
 Ro7-0213, GABA_A/benzodiazepine receptor, transmembrane topology, 75

S

- Saponin, permeabilized muscle cells, release, nonmitochondrial sequestered calcium, 369
 S49 cells, chronic somatostatin treatment and withdrawal, cAMP accumulation, 116
 Secobarbital, -mediated inactivation, liver cytochrome P-450, (rat), 10
 Somatostatin, chronic treatment and withdrawal, S49 cells, 116
 Sperm, P site-mediated inhibition of adenylate cyclase, cation and structural requirements, 681
 SR33557, receptor site identification, analysis, mode of action (rabbit), 766
 Stem cells, alterations, perinatal exposure, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (mouse), 18
 Steroids, 17 β -substituted, inactivation, hepatic progesterone hydroxylase, 148
 Stypoldione, selective inhibition of cytokinesis, embryo (sea urchin), 635
 Substantia nigra, differences in dopamine receptor reserve, *N*-*n*-propylnorapomorphine enantiomers, 125
 Sulfhydryl groups, selective inhibition of cytokinesis, low stypoldione, embryo (sea urchin), 635

T

- Tachyphylaxis, agonist-promoted sequestration, β_2 -adrenergic receptors, 132

- Tacrine, protection of acetylcholinesterase, inactivation, diisopropyl-fluorophosphate, 85
 Telenzepine, existence of stable enantiomers, interaction, muscarinic receptor subtypes (rat), 477
 Tetraabenazine, monoamine pool reduction, peripheral tissues (rat), 375
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
 characterization of specific binding protein, thymic epithelial cells (human), 713
 partial antagonism of induction, aryl hydrocarbon hydroxylase, 6-methyl-1,3,8-trichlorodibenzofuran (rat), 729
 perinatal exposure, lymphocyte stem cell alterations (mouse), 18
 Tetrahydroaminoacridine, antagonists of hippocampal M1 muscarinic receptors, 652
 Tetrahydrocannabinol, -induced catalepsy, immunization against prostaglandins (mouse), 6
 Tetrahydrocannabinols, conformational analysis, high resolution NMR, 495
 Thymidine kinase
 gene expression, inducible hybrid viral gene, model, 433
 mechanism of action, 5'-amino-2',5'-dideoxythymidine, 98
 Thymidylate synthase, modulation of 5-fluoro-2'-deoxyuridine response, folinic acid, colonic tumor cell lines (human), 422
 Thymus, epithelial cells, specific binding protein, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (human), 713
 Thyroid, hormones, interaction, vascular smooth muscle strips (rabbit), 760
 Thyroid peroxidase, bioactivation of phenytoin, 504
 Thyrotropin-releasing hormone, receptors, solubilization, pituitary (rat), 533
 Thyroxine, alteration of P-450 protein levels, hypophysectomy, liver (rat), 519
 Topoisomerase II, modulation of catalytic activity, DNA minor groove binding agents, 177
 Transglutaminase enzymes, mechanism-based inhibitor, cross-linked envelope formation, malignant keratinocytes (human), 701
 Tremorgen aflatoxin, positive allosteric modulator, GABA_A receptor channel, *Xenopus* oocytes, 319
 1,4,5-Trisphosphate, binding and metabolism in bovine adrenal cortex, calcium release activity, 339

U

- UK-14,304, full and partial agonist interactions, α -2 adrenoceptors, HT29 cells, 345

V

- Vincristine, VP-16 uptake, mechanisms of drug resistance (human), 271

Y

- Yeast, expression of human P-450IIC gene, galactose-inducible expression system, 443

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. William A. Catterall, Editor, *Molecular Pharmacology*, Department of Pharmacology, SJ-30, University of Washington, Seattle, Washington 98195, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baue, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7) Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers after such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (\times , \circ , \bullet , \square , \blacksquare , \triangle , \blacktriangle , \odot). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.


Newsworthy and timely
articles in your field

MOLECULAR PHARMACOLOGY

Editor: **William A. Catterall, PhD**, University of Washington, Seattle, Washington

Is your special interest receptors and neurotransmitters... drug metabolism... antibiotic and anticancer drug actions... or other areas related to the molecular basis of drug action? If so, you should be subscribing to **MOLECULAR PHARMACOLOGY**.

The editor's and editorial board's high standards ensure that the papers you read in **MOLECULAR PHARMACOLOGY** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. Start your subscription today to ensure access to the most newsworthy papers in your field.



Monthly

YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

Molecular Pharmacology (bimonthly)

☐ Individual: \$80/yr ☐ Institutions: \$175/yr

(Please add \$25.00 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city state zip _____

Payment options:

☐ Check enclosed ☐ VISA

☐ Bill me

☐ MasterCard

☐ American Express

card # _____

signature/P.O.# _____

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, in *US dollars only*. Rates valid for orders received before October 31, 1989.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request. *Residents, fellows, interns, and students*, when requesting the in training rate (to which you are entitled for 3 years), please specify training status and institution.

Rates subject to change without notice.

Williams & Wilkins

P.O. Box 23291
Baltimore, Maryland 21203

The Broadway Centre
2-6 Fulham Broadway
London SW6 1AA England

MOLA91 1159



Broad coverage of pharmacology
in a prestigious journal

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS


Editor: **Eva King Killam, PhD**, School of Medicine, University of California, Davis

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including:

- autonomic pharmacology
- analgesia
- behavioral pharmacology
- cardiovascular pharmacology
- cellular pharmacology
- chemotherapy
- clinical pharmacology
- developmental pharmacology
- drug abuse
- drug metabolism & disposition
- gastrointestinal pharmacology
- immunopharmacology
- neuropharmacology
- pulmonary pharmacology
- renal pharmacology
- toxicology

JPET is valuable reading for academic, industrial and clinical pharmacologists as well as toxicologists. The Journal deserves a place in every pharmaceutical and toxicological research laboratory and pharmacology/toxicology department throughout the world.

Monthly



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

The Journal of Pharmacology and Experimental Therapeutics
(monthly)

☐ Individual: \$150/yr ☐ Institutions: \$240/yr
(Please add \$55 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city state zip _____

Payment options:

☐ Check enclosed ☐ Bill me
☐ VISA ☐ MasterCard ☐ American Express

card # _____

signature/P.O.# _____

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. Rates valid for orders received before October 31, 1989.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request. *Residents, fellows, interns, and students*, when requesting the in-training rate (to which you are entitled for 3 years), please specify training status and institution.

Rates subject to change without notice.

Williams & Wilkins

P.O. Box 23291
Baltimore, Maryland 21203

The Broadway Centre
2-6 Fulham Broadway
London SW6 1AA England

PTA91 1171



INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202-3993 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. William A. Catterall, Department of Pharmacology, SJ-30, University of Washington, Seattle, WA 98195.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, \$80.00; institutional, \$175.00, single copy, \$16.00. FOREIGN: personal, \$105.00; institutional, \$200.00; single copy, \$19.00. JAPAN: personal, \$145.00; institutional, \$240.00 (includes air freight). (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost.

Japanese Yen price is available from our sole agent: USACO Corporation, 13-12 Shimbashi 1-Chome, Minato-Ku, Tokyo 105, Japan, telephone 03-502-6471.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions and renewals are entered to begin with the January or July issue.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD. 21202-3993 U. S. A.